Savara (NASDAQ:SVRA) Stock Price Down 5.1% – Should You Sell?

by · The Cerbat Gem

Shares of Savara Inc (NASDAQ:SVRA – Get Free Report) were down 5.1% during trading on Tuesday . The company traded as low as $3.51 and last traded at $3.51. Approximately 390,156 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 1,193,072 shares. The stock had previously closed at $3.70.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Savara in a research report on Tuesday, October 8th. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $11.17.

View Our Latest Research Report on Savara

Savara Trading Down 2.2 %

The stock has a 50 day moving average of $4.00 and a 200-day moving average of $4.24. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, sell-side analysts forecast that Savara Inc will post -0.44 EPS for the current year.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in SVRA. BNP Paribas Financial Markets grew its stake in Savara by 92.3% in the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after purchasing an additional 35,269 shares during the period. Jennison Associates LLC grew its stake in shares of Savara by 0.3% in the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Swiss National Bank purchased a new stake in shares of Savara in the first quarter worth $732,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Savara in the first quarter worth $394,000. Finally, ProShare Advisors LLC grew its stake in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Recommended Stories